Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of jaketinib hydrochloride tablets in active ankylosing spondylitis
CTR20231388Phase 3Completed
- Sponsor
- Zelgen
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of jaktinib in ankylosing spondylitis (AS), sponsored by Zelgen. Started Jul 2023; status: completed.
02
Drugs
jaktinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20231388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231388.